Kelly F. Bell, PharmD, MSPhr

Articles by Kelly F. Bell, PharmD, MSPhr

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD

April 8th 2019

The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

ByHuan Huang, PhD,Kelly F. Bell, PharmD, MSPhr,Ray Gani, PhD,Cathy W. Tugwell, RN, BSN,James M. Eudicone, MS, MBA,Michelle R. Krukas-Hampel, MA

April 13th 2018

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD

April 13th 2018

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD

April 13th 2018

Kelly F. Bell, PharmD, MSPhr

Articles by Kelly F. Bell, PharmD, MSPhr

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

Latest Updated Articles

Trending on AJMC

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD

Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD

Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts

The Bispecifics Network:

Advancing Bispecific Care Delivery in Community Oncology

Kelly F. Bell, PharmD, MSPhr

Articles by Kelly F. Bell, PharmD, MSPhr

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

Latest Updated Articles

Trending on AJMC

Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD

Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD

Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts